The Right Chondroitin Supplementation Activity Insulin Efficiency and Joints
Research shows that as insulin efficiency declines (insulin resistance advances), NO (nitric oxide) levels in the active chondrocyte tends to increase and oxidative control declines.
Original post: April 5, 2011
This translates into a higher risk for joint degeneration and inflammation.
In fact, one of the pharmacological actions of the PROPER chondroitin supplementation (research-supported molecular weight) is to ultimately inhibit NO elevation in these worker cells and allow the chondrocyte (the worker cell of the cartilage tissue that utilizesGAGs to rebuild collagen) to do its job undisturbed. Heavy arginine supplementation amidst an antioxidant compromised body, exposed to overexertion, and insulin resistance is a setting for joint degradation and inflammation. The solution is to use properly formulated performance products – no different from using properly formulated high performance engine oils when pushing your sports-mobile to the limit.
Nitric oxide (NO) is highly reactive and in the presence of the superoxide free radical is quickly converted to peroxynitrite (ONOO – ). This nasty free radical fuels inflammation and is known to damage DNA to kill cells. In fact, it is one fundamental way that our immune system uses NO to protect us from invading pathogens. The problem is, that once this inflammatory cycle starts, it can be self perpetuating turning NO into more ONOO – and intensifying the inflammatory activity in the proximate tissue.
Recent research demonstrates the pharmacological effects of the RIGHT chondroitin supplement. The controversy over whether chondroitin works or not has been ongoing. Our research at BNHR has demonstrated a functional role for chondroitin of low molecular form. >>> our findings are supported by independent work:
April 1, 2011 Researchers for a new study published online in the Annals of the Rheumatic Diseases say that supplemental chondroitin sulfate was found to significantly reduce the cartilage volume loss in patients withknee osteoarthritis in as little as six months into treatment, and reduced bone marrow lesions after 12 months of treatment. The researchers suggest that chondroitin sulfate helps protect joint structure….. ” Subjects were randomized to receive 800 mg of a “highly purified, pharmaceutical-grade” chondroitin sulfate or placebo, once daily, for six months. After six months, both the intervention and placebo groups were then given the 800-mg chondroitin dose once daily for another six months. Cartilage volume and bone marrow lesions were assessed by quantitative magnetic resonance imaging (qMRI) at baseline, six months, and 12 months. Synovial membrane thickness was assessed at baseline and at six months.”
the study report goes on to say:
“ Chondroitin sulfate slows the progression of the disease. This is an important finding, as a decrease in the rate of progression of cartilage loss in knee osteoarthritis patients, as seen by MRI, could potentially reduce the need for total knee replacement—a phenomenon that has been observed in other MRI clinical studies.”
He also noted, “It is important that patients are provided with highly purified pharmaceutical-grade chondroitin sulfate, the one used in this study, as this is the only one that can guarantee such efficacy and…safety results…”
Based on our canine and human studies at BNHR ..>>
‘pharmaceutical-grade chondroitin sulfate’ is probably referring to that low molecular weight form I so frequently speak and write about.